Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients.
Ontology highlight
ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease, characterized by impaired wound repair, tissue remodeling and fibrosis. Immune system may participate in the development and progression of the disease as indicated by altered activity in IPF sufferers. This study investigates the immune response to the BNT162b2 COVID-19 vaccine in patients with IPF compared to healthy controls, with a particular focus on evaluation of antibody responses, interferon-gamma release, cytokine profiling and a broad panel of immune cell subpopulations. IPF patients without prior exposure to SARS-CoV-2 had undetectable levels of anti-N IgG antibodies, highlighting their lack of previous infection. After vaccination, IPF patients showed a significant increase in anti-S1 IgG and IgA antibodies
SUBMITTER: Maciejewska A
PROVIDER: S-EPMC11750670 | biostudies-literature | 2024
REPOSITORIES: biostudies-literature
ACCESS DATA